KMB — Q2 2026 Financial Report Analysis

Overview

Kimberly-Clark's second quarter of 2026 (April 1 – June 30, 2026, reported August 4, 2026) showed an underlying business that is roughly flat on sales but more profitable, with reported earnings pulled down by deal costs and tax charges. Net sales rose 0.6% to $4,189 million, entirely from currency; organic sales were essentially flat (-0.1%). Gross margin jumped to 38.3% from 35.0%, helped by one-time tariff refunds and productivity savings. Diluted EPS from continuing operations fell to $1.22 from $1.33, and total diluted EPS fell 32% to $1.04. Those declines come from costs tied to the pending Kenvue acquisition and to the sale of a controlling stake in the international tissue business, not from weaker operations: adjusted EPS from continuing operations rose 10.4% to $1.80.

A structural note first: the International Family Care and Professional (IFP) business — Kimberly-Clark's tissue and professional-products business outside North America — is reported as a discontinued operation. The sales and operating profit figures below cover only the continuing business (North America and International Personal Care). The deal that moved IFP into a joint venture with Suzano, now called Arbex, closed on July 1, 2026, just after the quarter ended. Suzano paid about $1.7 billion for a 51% stake and Kimberly-Clark kept 49%.

Key figures

Organic sales growth strips out currency swings and exited businesses to show how much the ongoing business actually grew. Operating margin is operating profit as a share of sales — what's left after running the business, before interest and tax. "Adjusted" figures are the company's own non-GAAP measures that exclude restructuring, deal-related costs and other items management considers non-recurring.

Sales: currency did all the work

• North America (sales $2,698 million, -1.2%). Part of the decline is the planned exit from making private-label (store-brand) diapers in the US. The 0.7% organic decline has two specific causes named in the 10-Q: retailers cutting their inventories (about 1.0 point) and a fire at the company's Los Angeles distribution center (about 0.8 point). Without those, North American organic sales would have grown about 1%. Net prices fell 0.7% as the company spent on promotions to get shoppers to try new products.
• International Personal Care (sales $1,491 million, +4.0%). Most of the gain (3.1 points) was currency. Organic growth of 1.0% came from volume and better mix — more sales of higher-value products — in diapers and pants. That growth came despite a 140 bps hit from what the company calls false social-media allegations about the quality of certain of its diaper brands in China. Kimberly-Clark says independent testing by a government-certified third party confirmed the products' safety, but the episode "significantly impacted" its China diaper sales and is expected to keep weighing on sales and profit in the near term. At the total-company level, the China disruption cost about 50 bps of organic growth.

Margins: a one-time boost

Gross margin (the share of sales left after production costs) rose 330 bps on a reported basis. Part of that is only a comparison effect: last year's quarter carried $82 million of restructuring charges in cost of goods versus $22 million this year. On an adjusted basis the gain was 190 bps, to 38.8%. The 10-Q attributes it to one-time tariff refunds and about $120 million of productivity savings, partly offset by price cuts net of cost inflation. The filing does not quantify the tariff refunds, so we can't tell how much of the margin gain will carry forward. In the company's adjusted-operating-profit bridge, manufacturing costs (productivity plus refunds) added 14.2 points of growth, while lower volume took away 3.0 points and lower net pricing 2.8 points.

The segment view shows the same pattern. North America operating profit rose 10.7% to $725 million, driven by the tariff refunds and savings. International Personal Care operating profit rose only 2.2% to $186 million, after absorbing a 440 bps hit from the China disruption.

Why reported earnings fell

The operating improvement didn't reach the bottom line because of several large items:

• $109 million of Kenvue acquisition costs (advisory, legal, accounting) in operating profit, or $0.30 per share. Kimberly-Clark agreed in November 2025 to buy Kenvue (Tylenol, Listerine, Neutrogena) for 0.14625 KMB shares plus $3.50 in cash per Kenvue share: about 280 million new shares and about $6.7 billion in cash.
• A 37.9% effective tax rate (vs. 22.6%), mainly because of an $87 million tax charge on IFP earnings the company expects to bring back to the US ($0.26 per share).
• A $60 million loss from discontinued operations (vs. a $68 million profit), including $72 million of pre-tax IFP separation costs and $107 million of tax charges from reorganizing ahead of the IFP deal.
• Partly offsetting: a $39 million benefit from a favorable Brazilian tax ruling and lower restructuring charges ($54 million vs. $121 million).

Takeaway: The 10.4% rise in adjusted EPS rests on one-time tariff refunds and productivity savings, not on selling more: organic sales were flat, volume fell slightly and net pricing was negative. Kimberly-Clark is about to become a very different company (the tissue joint venture has closed and Kenvue is expected by year-end), so this quarter says more about how much cost-cutting headroom the company has than about how fast it can grow.

Cash and balance sheet

First-half operating cash flow (including discontinued operations) was $1,653 million vs. $1,097 million, mostly thanks to a $399 million working-capital inflow versus a $471 million outflow last year. Capital spending nearly doubled to $776 million. The company paid $843 million in dividends and bought back no shares, versus $120 million a year earlier. It raised $1,329 million of new debt. Continuing-operations debt stood at $6.5 billion at June 30, down from $7.2 billion at year-end.

Outlook

Management lowered its 2026 sales outlook and now expects:

• Organic sales growth about 1 point below the growth of its categories (currently about 2% on a trailing twelve-month basis). The company attributes about 1 point of total-company drag to the China disruption.
• Adjusted operating profit up mid-single digits in constant currency.
• Adjusted EPS from continuing operations up high-single digits in constant currency, including about a 30% rise in income from equity companies (partly owned businesses).
• Adjusted EPS attributable to Kimberly-Clark, which includes the tissue business now being handed to Arbex, down low-single digits in constant currency.

Our read: with first-half adjusted EPS from continuing operations up only 4.6% and one-time tariff refunds boosting Q2, reaching high-single-digit growth for the year requires the second half to accelerate while the China headwind continues. The main things to watch are whether North America volume recovers once the retailer destocking and Los Angeles fire effects pass, how fast China diaper sales recover, and the Kenvue closing, which will add roughly 280 million shares and new debt and make results from 2027 onward hard to compare with today's figures.